ClinicalTrials.gg
CompletedNCT00002325Updated Jun 24, 2005

A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common

An interventional study of Fluconazole in Mycoses, HIV Infections and Coccidioidomycosis, sponsored by Pfizer. Completed at 3 sites in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Primary conditionCoccidioidomycosisRegistry: MycosesReclassifiedWhy we changed it
Registry
Mycoses — the first condition term the registry derived for this study.
ClinicalTrials.gg
Coccidioidomycosis
Why
  1. The registry often attaches Mycoses to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Coccidioidomycosis, a narrower term within Mycoses.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Coccidioidomycosis with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Coccidioidomycosis · United States.

No phase
3 of 16
none open now
Registered
1st of 16
by date
Lead sponsor
2 of 16
Pfizer

Among the 16 studies in Coccidioidomycosis with a site in United States, this one is one of 3 with no phase, and was the 1st registered.

Coccidioidomycosis

21 studies on the registry are indexed under Coccidioidomycosis; 4 are open to participants now.

Browse Coccidioidomycosis studies →

Open to participants now

3 of the 16 studies in Coccidioidomycosis with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 2 Coccidioidomycosis studies recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Coccidioidomycosis with a site in United States, or all of them as a file.
02

Study summary

To compare the efficacy of fluconazole versus placebo in preventing the development of active coccidioidomycosis and other systemic fungal infections among HIV-infected patients with CD4 lymphocyte counts \< 250 cells/mm3 who are living in the coccidioidal endemic area.

Read the detailed description

Patients are randomized to receive either fluconazole or placebo daily.

03

Conditions studied

  • Mycoses
  • HIV Infections
  • Coccidioidomycosis

Keywords

  • Mycoses
  • Fluconazole
  • Acquired Immunodeficiency Syndrome
  • AIDS-Related Complex
  • Coccidioidomycosis
04

In context

Coccidioidomycosis Reclassified

21 studies on the registry are indexed under Coccidioidomycosis; 4 are open to participants now.

Browse Coccidioidomycosis studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Coccidioidomycosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Mycoses. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have:

  • Documented infection.
  • \< 250 cells/mm3.
  • No active coccidioidomycosis or other fungal disease requiring systemic antifungal therapy.
  • Residence in area considered to be endemic for Coccidioides immitis.
  • Consent of parent or guardian if under legal age of consent.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Unable to take oral medication.
  • Positive serum cryptococcal antigen.

Concurrent Medication:

Excluded:

  • Systemic antifungal therapy.

Patients with the following prior conditions are excluded:

History of to azole or imidazole compounds.

Prior Medication:

Excluded:

  • Systemic antifungal agents within 2 weeks prior to study entry.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Intervention model
Parallel assignment

Interventions

07

Study locations

3 sites
  • McDowell Clinic
    Phoenix, Arizona 85006, United States
  • Tucson Veterans Administration Med Ctr
    Tucson, Arizona 85723, United States
  • Dr Lawrence Cone
    Rancho Mirage, California 92270, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00002325
Lead sponsor
Pfizer
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 1996. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluconazole

Start the discussion